


Monday, February 15th 2016 undefined:28am ET - U.S. markets open in 1.5 hours and 2 minutes					
Nasdaq ▲ +70.67	4337.51 +1.66%	NYSE ▲ +199.80	9229.68 +2.21%	AMEX ▲ +30.60	2035.21 +1.53% S&P 500 ▲ +35.70

WallStreetSelect 114 Markets Stocks Funds Sectors Tools

Overview Market News Market Videos Currencies International Treasury & Bonds

Ticker Symbol or Company Name 

GET QUOTE Search InvestCenter ▶

Recent Quotes ▶ My Watchlist ▶ Indicators ▶ Local Stocks ▶

By: EIN Presswire February 15, 2016 at 05:36 AM EST

# MedGenome to discuss its proprietary cancer immunotherapeutics platform at the San Diego conference

The posters will be presented at the NGS Data Analysis and Informatics Conference, February 18–19, 2016 in San Diego, CA

SAN FRANCISCO, CA, UNITED STATES, February 15, 2016 /EINPresswire.com/ -- MedGenome announced today that they will present 2 posters at the NGS Data Analysis and Informatics Conference, which takes place on February 18–19, 2016 in San Diego, CA.

Details are below:

OncoPept: An integrated platform to develop novel therapeutics and biomarkers for cancer immunotherapy

OncoPept is an integrated platform that interrogates tumor and its microenvironment to discover potential cancer vaccine candidates as therapeutics and biomarkers of response. The platform selects neo-epitopes from genetic alterations including SNVs, indels and fusion genes to generate a library of peptides that are automatically interrogated through multiple prioritization steps to select vaccine candidates to evoke CD4+/CD8+ T-cell response. Additionally OncoPept provides an assessment of the tumor microenvironment by analyzing the immune and the stromal infiltrates within the tumor which are important predictors of response to cancer immunotherapy drugs.

OncoTope: A database of T-cell neo-epitopes from 540 cancer-causing genes mutated and/or overexpressed in 28 different cancers

OncoTope is a database of neo-antigens derived from genetic alterations in 540 cancer-causing genes across 28 different cancer types. The database captures CD4+/CD8+ T-cell neo-epitopes from 563,936 neo-antigens based on their binding affinity to 12-different HLA types and selected based on their expression in cancer cells. Mutated genes are rank ordered according to their T-cell neo-epitope burden.

Both the above products are MedGenome's proprietary platforms, and have been developed in-house for the NGS data analysis and bioinformatics needs.

About MedGenome

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit us at [www.medgenome.com](http://www.medgenome.com)

Hiranjith GH  
MedGenome  
+91-7022020883  
[email us here](#)